Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Larimar Therapeutics, Inc.LRMR · Entity 5634 | Chief Development Officer | January 26, 2026 | January 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Larimar Therapeutics, Inc.
Report date January 26, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,443 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 25,637 · Balance 76,443 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2036-01-26 | Direct | 153,822 |
Reported balance
After 2026-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-26 · Grant · Acquired 153,822 · Balance 153,822 F2: The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2: The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2026 Filed Jan 27, 2026 22:04 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 153,822 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001193125-26-024833 · ownership.xml · derivative · entry 2 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,822 Underlying: Common Stock · 153,822 shares Expires 2036-01-26 F2 · derivative.exercise_date: The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 22:04 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantCommon Stock | 25,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-024833 · ownership.xml · nonDerivative · entry 1 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,443 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:16 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 139,838 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001062993-25-001080 · form4.xml · derivative · entry 2 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,838 Underlying: Common Stock · 139,838 shares Expires 2035-01-22 F2 · derivative.exercise_date: The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:16 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantCommon Stock | 23,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001080 · form4.xml · nonDerivative · entry 1 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,806 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:33 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001062993-24-001086 · form4.xml · derivative · entry 2 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2034-01-17 F2 · derivative.exercise_date: The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:33 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001086 · form4.xml · nonDerivative · entry 1 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 21:08 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | PurchaseCommon Stock | 5,000 | $3.73 | $18,661.50 |
DisclosureSEC source: 0001062993-23-022200 · form4.xml · nonDerivative · entry 1 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.768, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 22:06 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0000899243-23-004438 · doc4.xml · derivative · entry 1 Shankar Gopi · CIK 0001965014 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2033-02-07 F1 · derivative.exercise_date: The option vests 25% on February 7, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.